The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Venetoclax plus FLAG-IDA in medically fit AML
Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase Ib/II study (NCT03214562) of venetoclax with standard intensive induction/consolidation therapy with FLAG-IDA in newly diagnosed or relapsed/refractory acute myeloid leukemia (AML). FLAG-IDA with venetoclax demonstrated activity in both settings, and the phase II portion of the study is ongoing. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
